Lilly, with Alzheimer's in its crosshairs, forms new neuroscience unit, unifies oncology under Loxo exec Psychedelics are getting closer to approval, but the market may not be ready Sanofi wanted to dump Translate Bio in April, but the mRNA biotech prevailed for a $3.2B deal instead Sponsored: Artificial Intelligence in Drug Discovery Requires Validated Data Going big: Bain reels in $1.9B for more mammoth biotech bets Qualigen calls it quits on COVID antiviral after pouring millions into R&D Aurinia stocks pipeline with $7M deal for 2 preclinical assets after securing crucial FDA nod Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells ResMed unveils new sleep apnea machine amid scramble to fill void left by Philips' CPAP recall Oracle of Organon: Buffett's Berkshire cashes out on Biogen, trims pharma holdings but discloses stake in Merck spinoff Surprise FDA rejection halts Sesen Bio's launch in its tracks, putting newly hired sales team in limbo HIMSS21: Facebook, YouTube say stamping out COVID misinformation is much more than 'plucking all the weeds' Featured Story | By Nick Paul Taylor Neuroscience has zoomed up the agenda at Eli Lilly as the combination of data on donanemab and the accelerated approval of Biogen’s Aduhelm has opened up an opportunity in Alzheimer’s disease. Lilly has responded by splitting off its late-phase neurodegeneration and pain prospects into a new business unit. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Investor interest is pushing psychedelics-based therapy mainstream and it’s now time to figure out the tricky regulatory issues that have held these therapies back, as the leading developer moves towards seeking approval in 2023. read more By Kyle LaHucik Sanofi was prepared to dump a quarter of its holding in Translate Bio in April—which the mRNA biotech agreed to. So how, exactly, did the French pharma end up buying Translate for $3.2 billion two weeks ago? Under-the-hood details of the deal were revealed in a Securities and Exchange Commission filing disclosed by Translate Monday. read more Sponsored By: BioIVT Machine-learning-based techniques in drug and diagnostic discovery require copious amounts of biomedical data, and that data needs to be validated to ensure success. read more By Nick Paul Taylor Bain Capital’s time in life science investing has been defined by big numbers: $720 million for its first fund, $1.1 billion for the second fund, $350 million for a single bet on Pfizer’s neuroscience pipeline. Now, Bain has made those numbers look small by reeling in a reported $1.9 billion for its third fund. read more By Annalee Armstrong The FDA wanted a couple more clinical studies for Qualigen’s investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Infectious disease medicine QN-165 will be shelved for now, as Qualigen shifts focus instead to its oncology pipeline, including QN-247 and RAS-F for a variety of cancers. read more By Kyle LaHucik With lupus nephritis med Lupkynis under its belt, Canadian biopharma Aurinia Pharmaceuticals is shelling out $7 million for two new preclinical assets to build out the next phase of its pipeline. The company has acquired Thunderbolt Pharma and inked a global licensing and research agreement with Riptide Bioscience to grow beyond Lupkynis, according to a Tuesday statement. read more By Arlene Weintraub CAR-T treatments like Novartis’ Kymriah have proven effective in some B-cell-driven cancers, with one notable exception: chronic lymphocytic leukemia. Researchers at the University of Pennsylvania showed in a new study that inhibiting BET proteins can improve CAR-T functioning by reviving exhausted T cells. read more By Andrea Park After Philips issued a recall in mid-June of nearly two dozen models of its continuous and noncontinuous ventilators, ResMed has eagerly stepped up to fill in the market gap left by Philips’ absence. read more By Angus Liu Unlike other high-tech stocks such as Amazon and Apple where Warren Buffett is playing the long game, the Oracle of Omaha was apparently in Biogen for the short run. read more By Beth Snyder Bulik Last week, Sesen Bio was finalizing label wording with the FDA on its bladder cancer hopeful Vicineum. This week, the CEO is explaining to investors how it will continue going forward after an FDA rejection. The unexpected FDA turn on Vicineum caught Sesen and its followers by surprise—but it’s far from alone lately. read more By Dave Muoio Beyond playing whack-a-mole with individual pieces of content, social media platforms need to take a proactive approach to developing and surfacing trustworthy information, representatives said during a HIMSS21 virtual panel. read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase. Sponsored by: Patheon by Thermo Fisher Scientific Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals. Sponsored by: Patheon by Thermo Fisher Scientific Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality. Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA Diversity, Equity & Inclusion Week November 9–11, 2021 | Virtual Event Fierce Biotech Forum Boston, MA | November 16-17, 2021 | 